Skip to main content

Table 1 Demographic and baseline characteristics of the study patients

From: Effect of switching from cinacalcet to etelcalcetide on secondary hyperparathyroidism in patients undergoing hemodialysis: an ESCORT trial

Cinacalcet dose before switching 25 mg/day (n = 53) 50 mg/day (n = 18) ≥ 75 mg/day (n = 19) Total (n = 90) P value
Female (%) 16 (30.2) 3 (16.7) 8 (42.1) 27 (30.0) P = 0.227
Age (year) 63.6 ± 8.7 61.6 ± 13.1 57.8 ± 10.8 62.0 ± 10.3 P = 0.106
Dry weight (kg) 59.2 ± 11.7 63.6 ± 17.4 58.7 ± 11.3 60.0 ± 12.9 P = 0.414
Systolic blood pressure (mmHg) 148.7 ± 25.0 144.8 ± 22.3 144.5 ± 18.0 147.0 ± 23.0 P = 0.717
Duration of dialysis (years) 15.1 ± 8.0 13.0 ± 6.7 16.5 ± 7.1 15.0 ± 7.6 P = 0.356
spKt/V 1.7 ± 0.3 1.6 ± 0.3 1.7 ± 0.2 1.7 ± 0.3 P = 0.540
cCa (mg/dL) 8.97 ± 0.40 9.07 ± 0.56 9.24 ± 0.41 9.05 ± 0.45 P = 0.074
Phosphate (mg/dL) 5.18 ± 1.09 5.64 ± 1.00 5.48 ± 1.34 5.34 ± 1.13 P = 0.272
Intact PTH (pg/mL) 180 ± 97 177 ± 123 289 ± 301 202 ± 170 P = 0.040
Alb (g/dL) 3.7 ± 0.3 3.8 ± 0.3 3.8 ± 0.3 3.8 ± 0.3 P = 0.317
Mg (mg/dL) 2.0 ± 0.3 2.6 ± 0.4 2.6 ± 0.3 2.5 ± 0.4 P = 0.106
  1. cCa corrected calcium, Intact PTH Intact parathyroid hormone, Alb albumin, Mg magnesium